[Neuropathic pain in oncology: mechanisms of its occurrence and current approaches to its treatment].
The paper provides evidence for the topicality of therapy for neuropathic pain syndrome (NPS) in cancer patients, describes the mechanisms of its occurrence, the specific features of its clinical manifestations, and presents a complex of currently available etiopathogenetic agents for the therapy of NPS. It also gives the authors' own data on the clinical application of the new anticonvulsant gabapentin (neurontin) in 34 patients with chronic NPS. The findings show the pronounced antineuropathic and analgesic effects of gabapentin in NPS. The side effects of the drug are not hazardous and they are moderately pronounced. These results are in agreement with the presented data of multicenter randomized placebo-controlled studies of the efficacy and tolerance of gabapentin in the treatment of cancer-induced NPS of various genesis.
Abuzarova
G R
GR
Osipova
N A
NA
D000328:Adult; D000368:Aged; D000588:Amines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000077206:Gabapentin; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000150:complications*; D009437:Neuralgia / Q000188:drug therapy* / Q000209:etiology*; D016032:Randomized Controlled Trials as Topic; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin